socalTECH

NOVEMBER 8, 2017

Venice, California-based Snap is set to see a punishing day on Wall Street, after reporting poorer than expected third quarter results last night, including poor user growth and sales. SNAP was already down around 12 percent in pre-market trading on Wednesday, falling from a close of $15.12 on Tuesday to around $13.33

Snapchat 113

Snapchat Venice .Net Report 113

Tech.Co

APRIL 11, 2018

Areas such as Oakland and San Francisco saw rent increases as high as 40 percent between 2015 and 2017. Plenty of workers have had enough: In the final quarter of 2017, according to real estate company Redfin , more residents left San Francisco than any other major U.S. LinkedIn’s April report on the state of the U.S.

Report 70

Report .Net Template Writing 70

Xconomy

NOVEMBER 13, 2016

I widened my net this year. million in a Series D round of investment capital, according to founder and chairman Tony Farwell. The startups selected for this year’s list began, as it did last year, with a master list of companies screened by the San Diego Venture Group for its annual venture summit.

San Diego 40

San Diego Technical Review Artificial Inteligence Startup 40

Startup Professionals Musings

SEPTEMBER 11, 2017

According to a recent Ernst & Young global report , the first half of 2017 was the most active first half by global number of IPOs since 2007. Public companies of any size must comply immediately with the full reporting requirements of the SEC. Violent market swings usually hit public companies first.

Startup 87

Startup Technical Review Report Entrepreneur 87

Xconomy

AUGUST 19, 2016

And once in a while, a defender uses his or her face, inadvertently, to block a ball spiked over the net. The CRISPR news this week doesn’t need a metaphor; the drama that MIT Technology Review reported can stand alone. STAT found the figures in Editas’s quarterly earnings report. Talk about sacrifice.

Technical Review 40

Technical Review Patents .Net Study 40

Xconomy

AUGUST 26, 2016

Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing. A Phase 2 trial of the drug, AMX0035, should start in late 2016 or early 2017. Alex Lash contributed to this report. . —Pfizer wasn’t done after scooping up Medivation.

Pricing 40

Pricing Thousand Oaks Startup Research 40